| Document |
Document Title |
|
WO/2024/074963A1 |
Methods and compositions of using transdermal delivery to facilitate delivery of a therapeutically effective amount of Naltrexone Hydrochloride, Naltrexol Hydrochloride, and/or Naltrexone Diol Ester for, for example, treatment of, for ex...
|
|
WO/2024/075803A1 |
The present invention addresses the problem of providing: a method for testing a cranial nerve disease including schizophrenia, or a method for testing the sensitivity to a cranial nerve disease; and a reagent and a kit for use in the te...
|
|
WO/2024/075696A1 |
The present invention addresses the problem of providing a novel compound having an SMG1 inhibitory activity and an anticancer effect, or a pharmaceutically acceptable salt thereof etc. A compound represented by formula (1) or a pharma...
|
|
WO/2024/074834A1 |
The present disclosure relates to an oral product, a process for producing the oral product, as well as to uses of said oral product. The oral product includes L-theanine, ginseng and lemon balm.
|
|
WO/2024/077054A1 |
The present disclosure relates to a protocol for the formulation and lyophilization of hydroxyl-terminated poly(ethylene glycol) (PEG) based block copolymer micelles without the use of excipients (cryo-protectants). The micelles are form...
|
|
WO/2024/076633A1 |
The present disclosure provides methods for treating an estrogen receptor mediated disease, disorder, or condition in a subject comprising administering to the subject a composition comprising Compound (1) or a pharmaceutically acceptabl...
|
|
WO/2024/076660A1 |
A combination therapy for use in treatment of substance abuse disorders, including alcohol use disorder (AUD) and opioid use disorder (OUD), includes both mitragynine (MG) and naltrexone (NTX). NTX is understood to be a mu opioid antagon...
|
|
WO/2024/076873A1 |
Provided are compounds which may be useful as inhibitors of CD73 for the treatment or prevention of cancer.
|
|
WO/2024/076985A2 |
Methods of treating SMARCA4-deleted cancer cells using a selective SMARCA2 degrader and a KRAS targeting therapy in a combination therapy is described.
|
|
WO/2024/076172A1 |
The present invention relates to an antiviral composition for coronavirus or influenza virus, using a natural product, and use thereof. The antiviral composition for coronavirus or influenza virus and a pharmaceutical composition for pre...
|
|
WO/2024/076657A1 |
3 β-hydroxy-5-cholestenoic acid 3-sulfate (CA3S), a sulfated derivative of 3β-hydroxy-5-cholestenoic acid (CA), is provided. Both CA and CA3S have potent cholesterol and triglyceride lowering and anti-inflammatory activities. Methods o...
|
|
WO/2024/075937A1 |
The present invention relates to a composition comprising a fucoidan fermentation product, and use thereof for improving the condition of the skin. Since low-molecular weight fucoidan can be induced when fucoidan is fermented using a Lac...
|
|
WO/2024/075082A1 |
Magnesium-infused and menthol-infused kinesiology tape is disclosed. The tape comprises an absorbent fabric substrate with adhesive on one side of the substrate to be applied to a person's skin and includes magnesium salt and menthol for...
|
|
WO/2024/076257A2 |
The invention relates to the field of medicine and, in particular, to a composition suitable for the treatment of patients with bacterial and viral and bacterial diarrhea, including unidentified and/or unspecified intestinal infections, ...
|
|
WO/2024/077203A1 |
Serotonin receptor modulators and methods of making and using the same are disclosed herein.
|
|
WO/2024/076693A1 |
Disclosed herein are compounds of Formula I and methods for using the same for treating or preventing an infection caused by a mycobacterium in a subject in need thereof. The method comprises administering to the subject the compound of ...
|
|
WO/2024/076781A1 |
The present disclosure relates to polynucleotides and methods of inhibiting the activities of development- associated pathways, including the Wnt, Hedgehog, and Notch pathways, and the invasive capacity of malignant cells to treat primar...
|
|
WO/2024/075051A1 |
Described herein are compounds of Formula I, wherein the variables are defined herein, their use as HSD17B13 inhibitors and/or degraders, pharmaceutical compositions containing such compounds and their use to treat, for example, NAFLD an...
|
|
WO/2024/077093A2 |
Described are compounds, compositions, and method for treating Penicillin Binding Protein 4 (PBP4) related diseases and/or disorders, such as bacterial infections.
|
|
WO/2024/077223A1 |
Disclosed herein are compounds with protein phosphatase 2A agonizing activity. In some embodiments, the compounds may be used in the treatment of cellular disorders, including cancer. In some embodiments, the compounds are used to treat ...
|
|
WO/2024/076731A1 |
The present invention provides compositions and methods for treating hidradenitis suppurativa (HS) or an apocrine gland infection. In one embodiment, the invention provides a method for treating HS or an apocrine gland infection in a sub...
|
|
WO/2024/075070A2 |
The present invention relates to a compound represented by chemical formula 1 as an SOS1 inhibitor, optical isomers thereof, stereoisomers thereof, solvates thereof, isotopic variants thereof, tautomers thereof, or pharmaceutically accep...
|
|
WO/2024/076999A2 |
Described herein are uses of 2',6-difluoro-5'-(3-(2-hydroxypropan-2-yl)imidazo[1,2-b][1,2
,4]triazin-7-yl)-[1,1'-biphenyl]-2-carbonitrile or a salt thereof. Also described herein are compositions, such as dosage forms, of 2',6-difluoro-5...
|
|
WO/2024/076674A1 |
The present disclosure provides compounds having activity as inhibitors of the G12C mutant KRAS protein, pharmaceutical compositions comprising the compounds, and methods of treating certain disorders, such as cancer, including but not l...
|
|
WO/2024/077283A2 |
Mitochondrial DNA (mtDNA) in humans is a 16,569 base pair double-stranded circular DNA that encodes 13 vital proteins of the electron transport chain. Embodiments of the invention include allotopic expression of mtDNA genes to compensate...
|
|
WO/2024/077148A1 |
The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the plasminogen (PLG) gene, as well as methods of inhibiting expression of PLG, and methods of treating subjects that would benefit from reduction i...
|
|
WO/2024/075794A1 |
Provided is a novel anti-influenza virus agent which inhibits the growth and infection mechanisms of influenza virus and thus has a target other than specific viral proteins and which does not cause the emergence of drug-resistant viruse...
|
|
WO/2024/077310A1 |
A preparation comprising the YEL002 compound as an active ingredient for the prevention or treatment of one or more diseases or conditions, and methods of using such preparations. The preparations may be a sublingual pill, an injection, ...
|
|
WO/2024/076677A2 |
Disclosed herein are imidazolyl-alkoxyquinolin-2-amines, pharmaceutical compositions comprising such compounds, and methods of using the compounds and compositions for treating or preventing inappropriate activation of a type I interfero...
|
|
WO/2024/077262A2 |
Disclosed are compositions and methods for reducing expression of ELAVL2. It has been determined that GGGGCC (G4C2) repeat expansion in the first intron of C9ORF72 is the most commonly known genetic cause of amyotrophic lateral sclerosis...
|
|
WO/2024/074127A1 |
Provided compounds of Formula (I), a tautomer thereof, a deuterated derivative of the compound or the tautomer, and a pharmaceutically acceptable salt of the foregoing, compositions comprising the compounds of Formula (I), a tautomer the...
|
|
WO/2024/030766A9 |
Provided herein are compositions and formulations for alleviating problems associated with unregulated intraocular pressure (IOP) in an eye comprising the administration of Trabodenoson. Administration of Trabodenoson results in reversin...
|
|
WO/2024/077036A1 |
This disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts thereof, and compounds of Formula (II), and pharmaceutically acceptable salts thereof, that inhibit phosphatidylinositol 4,5-bisphosphate 3-kinase (...
|
|
WO/2024/077087A2 |
The present technology relates generally to compounds for inhibiting M24B aminopeptidases to selectively activating the CARDS inflammasome, an innate immune signaling platform that triggers pyroptotic cell death.
|
|
WO/2024/074483A1 |
The present invention relates to compositions for use in the treatment, amelioration, and or prevention of myotonic dystrophy (DM) including DM1 and DM2. The compounds can disrupt the activity of Lin28 (e.g., Lin28A and/or Lin28B), RNA b...
|
|
WO/2024/075140A1 |
The present invention is in field of oral rehydration systems. More particularly, the present invention discloses rehydrating composition containing electrolytes along with postbiotic and zinc.
|
|
WO/2024/076177A1 |
The present invention relates to a pharmaceutical composition comprising enavogliflozin as an active ingredient for the prevention or treatment of diabetes and/or renal diseases in patients who have or are at risk of diabetes and/or rena...
|
|
WO/2024/076155A1 |
The present invention evaluated a method for producing a novel ENL/AF9 YEATS domain inhibitor, wherein the ENL/AF9 YEATS domain inhibition ability of a compound made through the production method was evaluated, and the novel compound was...
|
|
WO/2024/076530A1 |
This document provides methods and materials for treating a mammal (e.g., a human) having a disease or disorder condition associated with an elevated level of a plurality of senescence-associated secretory phenotype (SASP) polypeptides (...
|
|
WO/2024/074894A1 |
Micelle compositions comprising a hedgehog pathway inhibitor and their use in treating skin diseases, conditions, or disorders, such as skin cancers, including basal cell carcinoma, are disclosed.
|
|
WO/2024/077216A1 |
The disclosure is directed to compounds of Formula I (I). Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
|
|
WO/2024/073669A1 |
Provided herein are methods of treating neovascular age-related macular degeneration (nAMD) and diabetic retinopathy (DR) in a subject in need thereof comprising administering an anti-hVEGF treatment and a steroid treatment; wherein the ...
|
|
WO/2024/072437A1 |
The present disclosure provides method of administering sotorasib to a patient, e.g., a patient with a cancer comprising a KRAS G12C mutation, wherein the patient is further in need of treatment with a breast cancer resistance protein (B...
|
|
WO/2024/071371A1 |
The present disclosure provides a heterocyclic compound. The disclosure relates to a compound in which a ligand of a specific E3 ligase is bound to an intracellular target protein ligand via a linker. More specifically, the disclosure ...
|
|
WO/2024/069009A1 |
The present disclosure relates to a method of treating hepatocellular carcinoma in a human subject comprising administering an anti-Claudin-1 antibody to a human subject, wherein the hepatocellular carcinoma is resistant to sorafenib and...
|
|
WO/2024/071464A1 |
The present invention relates to anticancer uses of a maleate metal salt. Particularly, the present invention relates to a pharmaceutical composition for preventing or treating cancer and an anticancer adjuvant pharmaceutical composition...
|
|
WO/2024/067819A1 |
A piperidine-containing polycyclic derivative modulator, a preparation method therefor, and use thereof. In particular, the present invention relates to a compound represented by general formula (II-a), a preparation method therefor, a p...
|
|
WO/2024/073559A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
|
WO/2024/073077A1 |
Methods for treating or preventing a disease or infection with MCP-1 involvement, or related symptoms, using an effective amount of tafenoquine are disclosed. Compositions for treating or preventing a disease or infection with MCP-1 invo...
|
|
WO/2024/066986A1 |
The present invention relates to a 2-aminopyrimidine compound, and a use and pharmaceutical composition thereof. The compound can inhibit CDK4 and CDK6 activity, in particular CDK4 activity with high selectivity, and treat or prevent hyp...
|
